Status:
UNKNOWN
ARMA for Postoperative GERD After Sleeve Gastrectomy
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Gastroesophageal Reflux
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study is a pilot trial designed to evaluate the safety and efficacy of endoscopic anti-reflux ablation in postoperative gastroesophageal reflux after sleeve gastrectomy
Eligibility Criteria
Inclusion
- Patients with reflux symptoms after sleeve gastrectomy and are dependent on or refractory to PPI treatment
- Pathological esophageal acid exposure, defined by DeMeester score \>14.7 or acid exposure time (AET) \>4.2% on pH study
Exclusion
- Primary esophageal motility disorders
- Sliding hiatal hernia \>3cm
- Narrow gastric sleeve that precludes retroflexion of scope
- Gastric sleeve stricture
- Malignancy
- Pregnancy
- Patients not fit for general anesthesia
- Other cases deemed by the examining physician as unsuitable for safe treatment
- Refusal to participate
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05259579
Start Date
February 1 2022
End Date
July 31 2023
Last Update
February 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese University of Hong Kong
Hong Kong, Hong Kong